Inclusion Criteria:  Age 40-80 yrs at randomization Diagnosis of idiopathic pulmonary fibrosis (IPF), consistent with the ATS 2018 Guidelines Percent Forced Vital Capacity (%FVC) ≥50% and ≤90% Percent Carbon Monoxide Diffusing Capacity (%DLCO) ≥30% and ≤90% Willing and able to participate in an exercise regimen Ambulatory without the use of an assistive device Stable on antifibrotic therapy (pirfenidone or nintedanib) at least 3 months No changes in other medication for at least 4 wks before enrollment Must be able to read, write, and verbally communicate in English  Exclusion Criteria:  Forced expiratory volume in one second (FEV1)/FVC ratio <0.7 after administration of bronchodilator at screening Expected to receive a lung transplant within 1 year from randomization or, for patients at sites in the United States, on a lung transplant waiting list at randomization Known explanation for interstitial lung disease History of asthma or chronic obstructive pulmonary disease Active infection Ongoing IPF treatments including investigational therapy, immunosuppresents (other than prednisone 20 mg daily and below) and cytokine modulating agents Participation in a supervised exercise program including pulmonary rehab within the previous 12 months History of unstable or deteriorating cardiac or pulmonary disease (other than IPF) within the previous 6 months Major orthopedic, psychiatric, neurological, or other conditions that would impair performance of the study exercise outcomes Require >5LPM supplemental O2 at rest Currently pregnant